Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash & Current Investments (2021 - 2026)

Axsome Therapeutics' Cash & Current Investments history spans 6 years, with the latest figure at $305.1 million for Q1 2026.

  • On a quarterly basis, Cash & Current Investments rose 1.4% to $305.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $305.1 million, a 1.4% increase, with the full-year FY2025 number at $322.9 million, up 2.4% from a year prior.
  • Cash & Current Investments hit $305.1 million in Q1 2026 for Axsome Therapeutics, down from $322.9 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for AXSM hit a ceiling of $437.1 million in Q2 2023 and a floor of $73.4 million in Q2 2022.
  • Historically, Cash & Current Investments has averaged $289.4 million across 5 years, with a median of $315.4 million in 2024.
  • Biggest five-year swings in Cash & Current Investments: soared 495.57% in 2023 and later decreased 27.79% in 2024.
  • Tracing AXSM's Cash & Current Investments over 5 years: stood at $200.8 million in 2022, then surged by 92.29% to $386.2 million in 2023, then dropped by 18.34% to $315.4 million in 2024, then grew by 2.4% to $322.9 million in 2025, then dropped by 5.52% to $305.1 million in 2026.
  • Business Quant data shows Cash & Current Investments for AXSM at $305.1 million in Q1 2026, $322.9 million in Q4 2025, and $325.3 million in Q3 2025.